A COST‐EFFECTIVENESS MODEL OF ALTERNATIVE STATINS TO ACHIEVE TARGET LDL‐CHOLESTEROL LEVELS

SUMMARY An economic model was developed to estimate the relative cost‐effectiveness of alternative HMG‐CoA reductase inhibitors (statins) – atorvastatin, cerivastatin, fluvastatin, pravastatin and simvastatin – to achieve target low‐density lipoprotein cholesterol (LDL‐C) levels in a population of s...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	International journal of clinical practice (Esher) 2001-05, Vol.55 (4), p.243-249
Hauptverfasser:	Maclaine, GDH, Patel, H
Format:	Artikel
Sprache:	eng
Schlagworte:	Atorvastatin Calcium Biological and medical sciences Cardiovascular system Cholesterol, LDL - blood Coronary Disease - blood Coronary Disease - economics Coronary Disease - prevention & control Cost-Benefit Analysis Fatty Acids, Monounsaturated - economics Fatty Acids, Monounsaturated - therapeutic use Heptanoic Acids - economics Heptanoic Acids - therapeutic use Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors - economics Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use Indoles - economics Indoles - therapeutic use Medical sciences Miscellaneous Models, Economic Pharmacology. Drug treatments Pravastatin - economics Pravastatin - therapeutic use Pyridines - economics Pyridines - therapeutic use Pyrroles - economics Pyrroles - therapeutic use Simvastatin - economics Simvastatin - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!